Omalizumab and IgE in the Control of Severe Allergic Asthma
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for patients with the most severe type of bronchial as...
Saved in:
Main Authors: | Yasuhiro Gon (Author), Shuichiro Maruoka (Author), Kenji Mizumura (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective
by: Elena Camelia Berghea, et al.
Published: (2021) -
Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
by: Kariyawasam HH, et al.
Published: (2020) -
A challenging case of recalcitrant Hyper-IgE syndrome successfully treated with omalizumab
by: Rashid Shahid, et al.
Published: (2022) -
Sensitization to Mites and Total IgE in Allergic Children
by: Nivia López Ramírez, et al.
Published: (2013) -
Assessment of serum IgE levels in patients of allergic rhinitis
by: Mallikarjun S. Tegnoor, et al.
Published: (2017)